Medication Usage and the Risk of Neoplasia in Patients With Barrett's Esophagus
- 31 December 2009
- journal article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 7 (12) , 1299-1304
- https://doi.org/10.1016/j.cgh.2009.06.001
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Aspirin, Nonsteroidal Anti-inflammatory Drugs, and the Risks of Cancers of the EsophagusCancer Epidemiology, Biomarkers & Prevention, 2008
- Statins and Cancer RiskThe American Journal of Medicine, 2008
- Secondary Chemoprevention of Barrett's Esophagus With Celecoxib: Results of a Randomized TrialJNCI Journal of the National Cancer Institute, 2007
- Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidenceAlimentary Pharmacology & Therapeutics, 2006
- Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinomaAlimentary Pharmacology & Therapeutics, 2004
- Trends in Incidence and Prevalence of Specialized Intestinal Metaplasia, Barrett’s Esophagus, and Adenocarcinoma of the Gastroesophageal JunctionWorld Journal of Surgery, 2003
- Protective association of aspirin/NSAIDs and esophageal cancer: A systematic review and meta-analysisGastroenterology, 2003
- 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors and the Risk of CancerArchives of internal medicine (1960), 2000
- Barrett's oesophagus and proton pump inhibitors: a pathological perspectiveGut, 2000
- Symptomatic Gastroesophageal Reflux as a Risk Factor for Esophageal AdenocarcinomaNew England Journal of Medicine, 1999